Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
CDMOs are key players in the biopharma market, playing a vital role in translating science into medicines that change people’s lives.
Somehow it is already September which means we’re preparing for one of the key events in the biopharma calendar, at least if you’re involved in competitive intelligence –…
We're putting the finishing touches to our annual World Preview report - the forecasts are fascinating, but there's much to be uncertain about in the current…
At the recent BIO International convention, I was able to combine two of my favourite things - talking to customers and an excellent meal!
Evaluate Omnium is now officially an award-winning solution!
In December of 2022, Kite and Arcellx entered an agreement to develop and commercialise Arcellx’s multiple myeloma product candidate CART-ddBCMA.
A couple of weeks ago, we saw the return of BIO International to Boston for the first time since 2018.
Missed our gene editing webinar? Fear not! Here are a few of the highlights from our panel of experts which included Verve Therapeutics’ CEO, Sekar Kathiresan as well as…
With close to 20 years’ service at Evaluate, Jon Moser is pretty much woven into the fabric of the company – and its products. Now in the role of Chief Innovation Officer…
Gene editing has been in and out of the news since Crispr hit the headlines a decade ago. It’s been anything from the next big thing to a borderline miracle to a…